<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 23, 2000
ViroPharma Incorporated
-----------------------
(Exact name of issuer as specified in charter)
<TABLE>
<S> <C> <C>
DELAWARE 0-021699 23-2789550
(State or Other (Commission (I.R.S. Employer
Jurisdiction file Identification
of Incorporation or number) Number)
Organization)
</TABLE>
405 EAGLEVIEW BOULEVARD
EXTON, PENNSYLVANIA 19341
(Address of principal executive offices)
(610) 458-7300
(Registrant's telephone number, including area code)
<PAGE>
Item 5 - Other Events.
As is more fully described in the attached press release that is
incorporated herein by reference, on October 24, 2000, ViroPharma Incorporated
("ViroPharma") announced that it has sold to American Home Products Corporation
(NYSE: AHP) an additional 104,934 shares of ViroPharma's common stock for
---
$3,000,000 as a result of further progress made under the companies' hepatitis C
virus collaboration.
This report, including the press release attached hereto, contains forward-
looking statements that involve a number of risks and uncertainties, including
those relating to ViroPharma's continuing efforts to develop product candidates
for the treatment of hepatitis C. There can be no assurance that ViroPharma's
hepatitis C discovery and preclinical development efforts will be successful,
that clinical trials with product candidates emerging from such efforts can be
initiated on a timely basis, or at all, or that any such trials can be
successfully concluded. Investigational pharmaceutical products, such as
ViroPharma's product candidates for hepatitis C, require significant time and
effort for research and development, laboratory testing and clinical testing
prior to regulatory approval and commercialization. As a result, all of the
activities described in this report, including the press release attached
hereto, are subject to risks and uncertainties. Neither the FDA nor any other
regulatory authority has approved any of ViroPharma's product candidates for
commercialization. There can be no assurance that FDA or other regulatory
authority approval for any product candidate under development by ViroPharma
will be granted on a timely basis or at all. Even if approved, there can be no
assurance that such drug candidates will achieve market acceptance. These
factors, and other factors that could cause future results to differ materially
from the expectations expressed in this report, including the press release
attached hereto, include, but are not limited to, those described in
ViroPharma's most recent Registration Statement on Form S-3 filed with the
Securities and Exchange Commission. The forward-looking statements contained in
this report, including the press release attached hereto, may become outdated
over time. ViroPharma does not assume any responsibility for updating any
forward-looking statements.
Item 7 - Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
Exhibit No. Description
----------- -----------
99 ViroPharma Press Release dated October 24, 2000
<PAGE>
Signatures
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
ViroPharma Incorporated
Date: October 24, 2000 By: /s/ Michel de Rosen
-------------------
Michel de Rosen
President and Chief Executive Officer
<PAGE>
Index to Exhibits
Exhibit No. Description
----------- -----------
99 ViroPharma Press Release dated October 24, 2000
